Advanced biologic and cell and gene therapy production
Founded in 2001, Polyplus is a global biotechnology leader recognized for innovative and high performance transfection reagents and nucleic acid delivery solutions. With more than two decades of expertise, Polyplus empowers research laboratories, pharmaceutical companies, and biotechnology industries worldwide, facilitating breakthroughs in gene therapy, cell therapy, biologics manufacturing, genome editing, and advanced therapeutic development.
Polyplus’s specialized portfolio includes industry-leading transfection solutions such as:
jetOPTIMUS®: An advanced DNA transfection reagent providing remarkable transfection efficiency, superior cell viability, and minimal cytotoxicity, optimized for difficult-to-transfect cell lines and primary cells.
jetPRIME®: A versatile reagent designed for high-efficiency DNA and siRNA delivery into a broad spectrum of mammalian cell lines, ideal for gene silencing, expression, and functional genomics studies.
jetMESSENGER®: Optimized specifically for effective mRNA transfection, jetMESSENGER enables transient gene expression critical for vaccine research, protein production, and therapeutic mRNA delivery applications.
jetCRISPR™: Specifically tailored reagent for CRISPR/Cas9 gene editing workflows, facilitating high-efficiency genome editing in a variety of cell types, supporting therapeutic research, functional genetics, and drug discovery.
PEIpro® & FectoPRO®: Scalable solutions enabling reliable, high-yield, and cost-effective viral vector production, extensively employed in clinical-scale biomanufacturing of gene and cell therapy products.
Headquartered in Strasbourg, France, Polyplus maintains state-of-the-art production facilities and stringent quality standards, providing consistent, batch-to-batch reproducibility crucial for research and clinical applications. Committed to supporting clinical development, Polyplus also provides GMP-grade transfection reagents, meeting the stringent quality requirements essential for therapeutic applications and biologics production.
As an innovative biotechnology company, Polyplus consistently invests in advanced R&D, continually improving their products and technologies, ensuring researchers have access to cutting-edge solutions that accelerate scientific innovation, reduce experimental complexity, and enhance productivity.
Choosing Polyplus means partnering with a committed industry leader whose specialized expertise and advanced technologies are trusted worldwide, helping you achieve reliable and impactful results across gene therapy, genome editing, biomanufacturing, and molecular biology applications.